Drugs / CD19-CAR-DNT Cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06316076 | Oct 2023 → Jun 2024 | anti-neutrophil cytoplasmic antibody-associated vasculitis, idiopathic inflammatory myopathy, systemic lupus erythematosus, systemic sclerosis | RenJi Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05453669 | Jun 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19-CAR-DNT Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06316076 ↗ |
| Known as | RJMty19 | “A Clinical Study for the Safety and Efficacy of CD19-CAR-DNT Cells (RJMty19) in the Treatment of Relapsed or Refractory Autoimmune Diseases” NCT06316076 ↗ |
| Modality | Cell therapy | “Lentiviral vector-transduced DNT cells” NCT06316076 ↗ |
| Target | CD19 | “express anti-CD19 CAR” NCT05453669 ↗ |